U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109375) titled 'Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting' on July 10.
Brief Summary: PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
Study Start Date: Jan., 2026
Study Type: OBSERVATIONAL
Condition:
Fabry Disease
Intervention:
DRUG: pegunigalsidase alfa
Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
Recruitment Status: NOT_YE...